{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014254","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.425054+00:00","generated_at":"2026-05-30T05:46:06.799298+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback","bullets":["Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.","Net income $5.2M ($0.21 diluted) vs $22.3M in Q3 2023; adjusted EBITDA $10.7M vs $7.7M.","Gross margin improved to 75.0% from 70.9%; operating expenses up 16%.","FY2024 revenue guidance narrowed to $292-295M (prior $293-298M; growth 6-8%).","Board authorized up to $30M share repurchase program through Oct 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014254","json":"https://secwatch.observer/filing/0001558370-24-014254.json","markdown":"https://secwatch.observer/filing/0001558370-24-014254.md","text":"https://secwatch.observer/filing/0001558370-24-014254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837024014254/0001558370-24-014254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837024014254/tcmd-20241104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:46:06.799298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}